Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder

被引:6
作者
Wang, Liang-Jen [1 ,2 ]
Lee, Sheng-Yu [3 ,4 ]
Chou, Wen-Jiun [1 ,2 ]
Lee, Min-Jing [1 ,2 ]
Tsai, Ching-Shu [1 ,2 ]
Lee, Tung-Liang [5 ]
Yang, Chun-Ju [6 ]
Yang, Kang-Chung [6 ]
Chen, Chih-Ken [6 ,7 ,8 ]
Shyu, Yu-Chiau [6 ,9 ,10 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Child & Adolescent Psychiat, Kaohsiung, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Vet Gen Hosp, Dept Psychiat, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Sch Med, Grad Inst Med, Dept Psychiat,Coll Med, Kaohsiung, Taiwan
[5] Soochow Univ, Dept Microbiol, Taipei, Taiwan
[6] Keelung Chang Gung Mem Hosp, Community Med Res Ctr, Keelung 204, Taiwan
[7] Chang Gung Mem Hosp, Dept Psychiat, Keelung, Taiwan
[8] Chang Gung Univ, Coll Med, Keelung, Taiwan
[9] Acad Sinica, Inst Mol Biol, Taipei, Taiwan
[10] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan
关键词
ADHD; comorbidity; testosterone; epidemiology; psychostimulant; ENDOCRINE DISRUPTORS; STIMULANT MEDICATION; TESTOSTERONE; EXPOSURE; PARAMETERS; CHILDREN; SYSTEM; BRAIN;
D O I
10.1089/cap.2018.0126
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: Treating attention-deficit/hyperactivity disorder (ADHD) with methylphenidate (MPH) has become increasingly common, while both animal studies and case reports have previously suggested that MPH may exert adverse effects on the reproductive system or gonadal hormones. This study aims to investigate whether long-term MPH treatment of boys with ADHD can induce testicular dysfunction (TD). Methods: A nationwide cohort that included 59,746 boys diagnosed with ADHD and 52,008 healthy subjects retrieved from the National Health Insurance database in Taiwan was also observed between 1999 and 2011. TD was defined by the International Classification of Diseases, 9th revision, Clinical Modifications codes (257.0, 257.1, 257.2, 257.8, or 257.9). Cumulative time of MPH use was categorized into nonuse, short-term use (1-365 days), and long-term use (>365 days). We compared the rate of TD diagnosis between ADHD patients and controls and analyzed the risk of developing a TD after MPH treatment. Results: Compared with the control group (0.06%), the ADHD group had a higher comorbidity rate of TD (0.14%) (adjusted odds ratio [aOR] = 1.95, 95% confidence interval [95% CI]: 1.26-3.04, p = 0.003). However, MPH did not significantly influence the risk of developing TD (adjusted hazard ratio = 1.40, 95% CI: 0.77-2.54, p = 0.272). Compared with ADHD boys without MPH treatment, patients who were prescribed short-term MPH (aOR = 0.96, 95% CI: 0.51-1.82, p = 0.900) and long-term MPH (aOR = 1.40, 95% CI: 0.69-2.83, p = 0.351) showed no significance associated with an increased risk of developing TD. Conclusions: Our nationwide cohort showed that long-term treatment with MPH has no harmful effect on the testosterone function of ADHD patients. However, due to the increased comorbidity rate of ADHD and TD, early recognition and detection of TD in ADHD children have the potential to change the trajectory of TD morbidity later in life.
引用
收藏
页码:433 / 438
页数:6
相关论文
共 50 条
  • [21] Neurofunctional Effects of Methylphenidate and Atomoxetine in Boys with Attention-Deficit/Hyperactivity Disorder During Time Discrimination
    Smith, Anna
    Cubillo, Ana
    Barrett, Nadia
    Giampietro, Vincent
    Simmons, Andrew
    Brammer, Mick
    Rubia, Katya
    [J]. BIOLOGICAL PSYCHIATRY, 2013, 74 (08) : 615 - 622
  • [22] Symptoms of Attention-Deficit/Hyperactivity Disorder in Long-Term Survivors of Childhood Leukemia
    Krull, Kevin R.
    Khan, Raja B.
    Ness, Kirsten K.
    Ledet, Davonna
    Zhu, Liang
    Pui, Ching-Hon
    Howard, Scott C.
    Srivastava, Deo Kumar
    Sabin, Noah D.
    Hudson, Melissa M.
    Morris, E. Brannon
    [J]. PEDIATRIC BLOOD & CANCER, 2011, 57 (07) : 1191 - 1196
  • [23] Treatment of Attention-Deficit/Hyperactivity Disorder
    Pierce, Karen
    [J]. PEDIATRIC ANNALS, 2011, 40 (11): : 556 - 562
  • [24] Quantifying the Benefits and Risks of Methylphenidate as Treatment for Childhood Attention-Deficit/Hyperactivity Disorder
    Shaw, Philip
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (18): : 1953 - 1955
  • [25] Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options
    Hodgkins, Paul
    Shaw, Monica
    Coghill, David
    Hechtman, Lily
    [J]. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2012, 21 (09) : 477 - 492
  • [26] A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder
    Nagy, Balazs
    Setyawan, Juliana
    Coghill, David
    Soroncz-Szabo, Tamas
    Kalo, Zoltan
    Doshi, Jalpa A.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (03) : 283 - 292
  • [27] Effect of Methylphenidate on Motivation in Children With Attention-Deficit/Hyperactivity Disorder
    Chelonis, John J.
    Johnson, Teresa A.
    Ferguson, Sherry A.
    Berry, Kimberly J.
    Kubacak, Brian
    Edwards, Mark C.
    Paule, Merle G.
    [J]. EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2011, 19 (02) : 145 - 153
  • [28] The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder
    Szobot, CM
    Ketzer, C
    Cunha, RD
    Parente, MA
    Langleben, DD
    Acton, PD
    Kapczinski, F
    Rohde, LAP
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (03) : 423 - 426
  • [29] The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder
    Claudia M. Szobot
    Carla Ketzer
    Renato D. Cunha
    Maria A. Parente
    Daniel D. Langleben
    Paul D. Acton
    Flávio Kapczinski
    Luis A. P. Rohde
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 423 - 426
  • [30] Normalisation of frontal theta activity following methylphenidate treatment in adult attention-deficit/hyperactivity disorder
    Skirrow, Caroline
    McLoughlin, Grainne
    Banaschewski, Tobias
    Brandeis, Daniel
    Kuntsi, Jonna
    Asherson, Philip
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (01) : 85 - 94